Avecho Biotechnology Limited (ASX:AVE)

Market Cap	14.28M
Revenue (ttm)	1.13M
Net Income (ttm)	-3.12M
Shares Out	3.17B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	511,135
Average Volume	2,870,524
Open	0.0050
Previous Close	0.0050
Day's Range	0.0040 - 0.0050
52-Week Range	0.0010 - 0.0090
Beta	1.09
RSI	49.09
Earnings Date	May 26, 2025

About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its human health portfolio covers delivery of pharmaceutical products for pain and dermatology applications through gels, injectables, and patches. In additio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVE

Financial Performance

In 2024, Avecho Biotechnology's revenue was 1.13 million, an increase of 139.19% compared to the previous year's 473,551. Losses were -3.12 million, -9.15% less than in 2023.